# DESCRIPTION

## BACKGROUND OF THE INVENTION

- introduce field of invention
- describe background art in cardiovascular medicine
- motivate need for metastatic risk stratification
- describe molecular oncology research
- introduce Met oncogene product
- describe Met's role in cancer progression
- discuss correlation of Met-HGF expression with clinical outcome
- summarize research on Met expression in breast and prostate carcinomas
- motivate use of Met as a molecular imaging and therapeutic target
- describe prior art on anti-Met antibodies
- introduce approach of present inventors

## Tumor Imaging

- introduce radioimmunoscintigraphy as a molecular imaging modality
- describe advantages of scintigraphy
- discuss radiopharmaceuticals for imaging neoplasms

## SUMMARY OF THE INVENTION

- introduce novel antibody-based agents
- describe antibodies specific for Met oncogene protein product
- characterize mAbs against human Met (hMet) and human HGF (hHGF)
- report imaging of tumors using radiolabeled mAbs
- describe production and characterization of anti-hMet mAbs
- detail deposition of hybridoma cell lines in American Type Culture Collection
- describe binding of anti-hMet mAbs to hMet in immunoassay
- report detection of tumors using radiolabeled anti-hMet mAbs
- describe agonist and antagonist properties of anti-hMet mAbs
- introduce humanized mAb specific for Met
- describe composition comprising mAb, fragment, or derivative

## BRIEF DESCRIPTION OF THE DRAWINGS

- describe FIGS. 1A-1D, immunofluorescence analysis of tumors
- describe FIG. 2, total body images of tumor-bearing mice
- describe FIGS. 3A and 3B, ROI comparison of tumors
- describe FIG. 4, schematic representation of radiolabeled mAb binding
- describe FIGS. 5A-5C, characterization of anti-Met mAb "Met3"
- describe FIG. 6, Met expression by selected human cancer cell lines
- describe FIGS. 7-13, scintigrams of tumor xenografts and FACS analysis

## DESCRIPTION OF THE PREFERRED EMBODIMENTS

- correlate Met and HGF expression with poor prognosis
- describe animal models for nuclear imaging of Met and HGF expression
- disclose visualization of Met-expressing tumor xenografts
- describe uptake and turnover of radiolabeled mAbs
- incorporate references to known methodologies
- define antibodies and immunoglobulin molecules
- describe variable and constant regions of antibodies
- explain antigen-binding fragments of antibodies
- define monoclonal antibodies and their production
- describe chimeric antibodies and their production
- explain humanized antibodies and their production
- describe choice of human V domains for humanized antibodies
- explain design of humanized antibodies using 3D models
- describe production of human antibodies in transgenic animals
- describe production of human antibodies in phage display libraries
- describe chimeric molecules with extended in vivo half-life
- describe diabodies and anti-idiotypic antibodies

### Antibody Functional Derivatives and Chemically Modified Antibodies

- introduce chemical modifications of anti-Met antibodies
- describe derivatization with bifunctional agents
- list crosslinking agents
- describe reactive water-insoluble matrices
- summarize other modifications
- describe deamidation of glutaminyl and asparaginyl residues
- describe hydroxylation of proline and lysine
- describe phosphorylation of hydroxyl groups
- describe methylation of a-amino groups
- describe acetylation of the N-terminal amine
- describe amidation of any C-terminal carboxyl group
- describe alteration of native glycosylation pattern
- describe bonding to nonproteinaceous polymers
- introduce antibody functional derivatives and chemically modified antibodies
- describe fluorescent labeling methods
- describe radionuclide labeling methods
- describe phosphorescent and chemiluminescent labeling methods
- describe colorimetric detection methods
- describe in situ detection methods
- describe diagnostic in vivo radioimaging methods
- describe radioimmunoscintigraphic analysis methods
- describe Met-directed nuclear imaging study methods
- describe tumor diagnosis and therapy methods
- describe reagent compositions and utility
- describe immunoassay techniques
- describe affinity ligands and solid phase separation methods

### Pharmaceutical and Therapeutic Compositions and their Administration

- describe pharmaceutical compositions
- introduce compounds and their salts
- discuss effective dosages and schedules
- provide guidance on selecting appropriate doses
- describe administration in combination with other therapeutic agents
- discuss therapeutic agents contemplated
- introduce pharmaceutical preparations and their manufacture
- describe topical application and aerosol preparations
- discuss preferred topical applications
- introduce therapeutic conjugates and labeled antibodies
- describe radionuclide conjugates and their use
- discuss boron neutron capture therapy
- introduce other therapeutic agents and their use
- discuss lectins and toxins
- describe cytotoxic drugs and their use

### Therapeutic Methods

- introduce therapeutic methods for inhibiting tumor growth and invasion
- discuss administration of therapeutic antibody compositions

### Anti-Met mAb Characterization

- describe scatter assay for neutralizing or activating activity
- discuss urokinase plasminogen activator-plasmin proteolytic assay

### Articles of Manufacture and Kits

- introduce articles of manufacture and kits for diagnosing, imaging, treating, detecting, quantitating, or purifying Met

## EXAMPLE 1

### Materials and Methods

- list reagents
- describe cell lines and tumors
- produce and characterize anti-HGF mAbs
- produce and characterize anti-Met mAbs
- radioiodinate and inject mAb mixture
- describe imaging procedures and analysis
- summarize imaging results

## EXAMPLE 2

### Characterization of Anti-Met mAb by Immunofluorescence

- characterize anti-Met mAb by immunofluorescence

## EXAMPLE 3

### Image Analysis and Quantitation

- describe image analysis and quantitation
- summarize results of ROI analysis
- discuss significance of results
- describe negative and positive control studies

## DISCUSSION OF EXAMPLES 1-3

- demonstrate imaging of tumors with 125I-labled mAb mixture
- discuss differences in in vivo metabolism of 125I-mAb mixture by human and murine tumors

### EXAMPLE 4

- introduce radioimmunoscintigraphy of hMet-expressing tumor xenografts using Met3
- describe preparation and characterization of Met3
- analyze Met expression by cell lines
- describe radioiodination and injection of Met3
- outline imaging procedures and analysis
- characterize Met3
- analyze Met expression by cell lines
- perform image analysis and quantitation
- discuss results of imaging studies
- correlate Met3 uptake with Met abundance in tumor cells
- discuss implications for tumor imaging and diagnosis
- conclude that Met3 is useful for imaging hMet-expressing xenografts

### EXAMPLE 5

- introduce a new mAb, Met5, and its production and characterization
- demonstrate binding of Met5 to canine Met and human Met
- perform nuclear imaging of human tumor xenografts with 125I-Met5

